BNP Paribas Health Cr Innovtr Cl Cap |
Performance History | 30/04/2024 |
Growth of 1,000 (EUR) |
Fund | 9.5 | 18.8 | 1.1 | 0.3 | 8.8 | |
+/-Cat | -1.7 | 2.2 | 10.9 | 1.1 | 5.4 | |
+/-Idx | - | -7.2 | 1.0 | 0.5 | 2.5 | |
Category: Sector Equity Healthcare | ||||||
Benchmarks: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 16/05/2024 | EUR 1700.93 | |
Day Change | -0.68% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0823416762 | |
Fund Size (Mil) 16/05/2024 | EUR 1659.48 | |
Share Class Size (Mil) 16/05/2024 | EUR 1191.32 | |
Max Initial Charge | 3.00% | |
Ongoing Charge 29/04/2024 | 1.98% |
Investment Objective: BNP Paribas Health Cr Innovtr Cl Cap |
Increase the value of its assets over the medium term by investing in healthcare innovative companies. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Jon Stephenson 02/05/2016 | ||
Christian Fay 09/07/2018 | ||
Inception Date 17/05/2013 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care 10/40 NR EUR | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for BNP Paribas Health Cr Innovtr Cl Cap | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.19 |
UnitedHealth Group Inc | Healthcare | 6.95 |
AstraZeneca PLC | Healthcare | 6.27 |
Sanofi SA | Healthcare | 5.15 |
Boston Scientific Corp | Healthcare | 4.78 |
Increase Decrease New since last portfolio | ||
BNP Paribas Health Cr Innovtr Cl Cap |